Published in Antimicrob Agents Chemother on November 01, 1983
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother (1984) 6.81
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother (1984) 3.04
Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother (1984) 2.79
Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother (1985) 2.51
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1986) 2.29
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother (1986) 2.26
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 2.02
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother (1988) 1.88
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother (1986) 1.79
Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (1986) 1.74
Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals. Antimicrob Agents Chemother (1985) 1.56
Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother (1986) 1.49
Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis. Antimicrob Agents Chemother (1984) 1.48
Comparative double-blind study of 200- and 400-mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhea in males. Antimicrob Agents Chemother (1987) 1.47
A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 1.37
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats. Antimicrob Agents Chemother (1988) 1.37
Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob Agents Chemother (1992) 1.37
In vitro evaluation of A-56619 and A-56620, two new quinolones. Antimicrob Agents Chemother (1986) 1.36
Characterization of the porins of Campylobacter jejuni and Campylobacter coli and implications for antibiotic susceptibility. Antimicrob Agents Chemother (1989) 1.29
In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients. Antimicrob Agents Chemother (1984) 1.25
In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents. Antimicrob Agents Chemother (1985) 1.13
Bone penetration of enoxacin in patients with and without osteomyelitis. Antimicrob Agents Chemother (1988) 1.09
In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin). Antimicrob Agents Chemother (1985) 1.07
Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis. Antimicrob Agents Chemother (1985) 1.01
Interaction of the fluoroquinolone antimicrobial agents ciprofloxacin and enoxacin with liposomes. Antimicrob Agents Chemother (1989) 0.95
Clinical overview of enoxacin. Clin Pharmacokinet (1989) 0.93
Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem (2012) 0.89
MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids. Infection (1991) 0.89
Comparative effects of enoxacin and norfloxacin on human colonic microflora. Antimicrob Agents Chemother (1987) 0.88
In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria. Antimicrob Agents Chemother (1984) 0.86
Synthesis, characterization, antibacterial and anti-inflammatory activities of enoxacin metal complexes. Bioinorg Chem Appl (2009) 0.83
Proposed quality control and interpretive criteria for disk diffusion susceptibility testing with enoxacin. J Clin Microbiol (1985) 0.82
Enoxacin penetration into human prostatic tissue. Antimicrob Agents Chemother (1988) 0.81
Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections. Clin Pharmacokinet (1989) 0.80
Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains. Antimicrob Agents Chemother (1984) 0.78
[Enoxacin concentration in seminal fluid, in prostate secretions and in prostatic adenoma tissue following oral administration or intravenous infusion]. Infection (1989) 0.78
In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. Infection (1986) 0.78
Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study. Br J Clin Pharmacol (1988) 0.75
Tissue penetration and clinical efficacy of enoxacin in urinary tract infections. Clin Pharmacokinet (1989) 0.75
[Enoxacin: spectrum and activity of its antibacterial effect]. Infection (1986) 0.75
The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. Infection (1986) 0.75
Ofloxacin treatment in the management of chronic osteitis. Drugs (1987) 0.75
In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother (1980) 26.28
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1982) 10.08
Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis (1974) 9.38
Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrob Agents Chemother (1983) 6.06
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother (1983) 5.45
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound. Antimicrob Agents Chemother (1983) 4.00
The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. J Biol Chem (1965) 22.76
Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother (1974) 10.72
HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1979) 10.60
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1982) 10.08
Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. Antimicrob Agents Chemother (1979) 10.01
Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases. Antimicrob Agents Chemother (1974) 9.66
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1984) 8.62
beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob Agents Chemother (1978) 8.28
Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother (1979) 7.65
Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother (1978) 7.39
The new beta-lactamase-stable cephalosporins. Ann Intern Med (1982) 7.20
Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity. Antimicrob Agents Chemother (1978) 5.81
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Purification and characterization of penicillinases from Salmonella typhimurium and Escherichia coli. Arch Biochem Biophys (1970) 5.39
Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins. Antimicrob Agents Chemother (1978) 4.69
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother (1982) 4.45
Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother (1978) 4.28
Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother (1978) 4.27
Release of surface enzymes in Enterobacteriaceae by osmotic shock. J Bacteriol (1967) 4.05
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother (1986) 3.98
Carbenicillin: clinical and laboratory experience with a parenterally administered penicillin for treatment of Pseudomonas infections. Ann Intern Med (1969) 3.62
On the surface localization of enzymes in E. coli. Biochem Biophys Res Commun (1964) 3.52
Relation of beta-lactamase activity and cellular location to resistance of Enterobacter to penicillins and cephalosporins. Antimicrob Agents Chemother (1972) 3.50
Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1981) 3.50
In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1984) 3.45
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin. Antimicrob Agents Chemother (1984) 3.40
In vitro study of netilmicin compared with other aminoglycosides. Antimicrob Agents Chemother (1976) 3.35
In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1976) 3.25
In vitro studies of tobramycin, an aminoglycoside antibiotic. Antimicrob Agents Chemother (1972) 3.23
Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. Antimicrob Agents Chemother (1975) 3.17
Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother (1980) 3.14
Infective endocarditis--an evolving disease. A review of endocarditis at the Columbia-Presbyterian Medical Center, 1968-1973. Medicine (Baltimore) (1978) 3.03
In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother (1983) 3.00
Comparative inhibition beta-lactamases by novel beta-lactam compounds. Antimicrob Agents Chemother (1979) 2.97
The surface localization of penicillinases in Escherichia coli and Salmonella typhimurium. Biochem Biophys Res Commun (1968) 2.76
The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J Antibiot (Tokyo) (1979) 2.67
Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother (1979) 2.67
Infective endocarditis at the Presbyterian Hospital in New York City from 1938-1967. Am J Med (1971) 2.66
The 5'-nucleotidase of Escherichia coli. I. Purification and properties. J Biol Chem (1967) 2.59
Antibacterial activity of a monocyclic beta-lactam SQ 26,776. J Antimicrob Chemother (1981) 2.59
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA (1981) 2.55
Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother (1988) 2.52
Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria. Antimicrob Agents Chemother (1976) 2.42
Cefaclor: in vitro spectrum of activity and beta-lactamase stability. Antimicrob Agents Chemother (1978) 2.42
Testing the physician's knowledge of antibiotic use: Self-assessment and learning via videotape. N Engl J Med (1975) 2.35
Septicemia with non-typhoid salmonella. Medicine (Baltimore) (1974) 2.31
Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 2.26
Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620. Antimicrob Agents Chemother (1986) 2.26
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis (1996) 2.23
New macrolide antibiotics: azithromycin and clarithromycin. Ann Intern Med (1992) 2.22
Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases. Am J Med (1985) 2.15
Bone and joint infections due to Salmonella. J Infect Dis (1978) 2.14
Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa. Lancet (1986) 2.14
Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. Am J Med (1987) 2.13
In vitro activity of S-ofloxacin. Antimicrob Agents Chemother (1989) 2.10
Antimicrobial resistance and R-factor transfer among isolates of Salmonella in the northeastern United States: a comparison of human and animal isolates. J Infect Dis (1975) 2.09
Direct detection and amplification of Helicobacter pylori ribosomal 16S gene segments from gastric endoscopic biopsies. Diagn Microbiol Infect Dis (1991) 2.06
In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother (1994) 2.03
The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther (1985) 1.99
In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338. Antimicrob Agents Chemother (1989) 1.94
The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med (1977) 1.93
Rapid, reproducible enzyme immunoassay for gentamicin. J Clin Microbiol (1980) 1.92
In vitro studies of cephanone, a 3-heterocyclic-thiomethyl cephalosporin derivative. J Antibiot (Tokyo) (1973) 1.90
Oligonucleotide probe for detection and identification of Campylobacter pylori. J Clin Microbiol (1989) 1.90
Antibacterial activity and beta-lactamase stability of temocillin. Antimicrob Agents Chemother (1982) 1.87
A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot (Tokyo) (1978) 1.82
In vitro activity of sparfloxacin. Antimicrob Agents Chemother (1991) 1.79
The nephrotoxicity of antimicrobial agents (second of three parts). N Engl J Med (1977) 1.79
In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother (1986) 1.79
Comparative in vitro activity of a new quinolone, AM-1091. Antimicrob Agents Chemother (1989) 1.78
In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. J Antimicrob Chemother (1985) 1.78
Semisynthetic penicillin 6-(D(--)-alpha-carboxy-3-thienylacetamido) penicillanic acid active against Pseudomonas in vitro. Appl Microbiol (1971) 1.77
Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis (1976) 1.77
Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. J Infect Dis (1978) 1.75
In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105. Antimicrob Agents Chemother (1988) 1.75
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Antimicrob Agents Chemother (1986) 1.74
Gentamicin in 1978. Ann Intern Med (1978) 1.73
In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins. Antimicrob Agents Chemother (1982) 1.70
In vitro activity and beta-lactamase stability of U-63196E, a novel cephalosporin. Antimicrob Agents Chemother (1983) 1.69
Inactivation of beta-lactam antibiotics by Legionella pneumophila. Antimicrob Agents Chemother (1979) 1.69
Digoxin-inactivating bacteria: identification in human gut flora. Science (1983) 1.68
Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother (1989) 1.67
Kinetics of mezlocillin and carbenicillin. Clin Pharmacol Ther (1978) 1.65
Postsplenectomy infection. Surg Clin North Am (1981) 1.63
In vitro activity and beta-lactamase stability of BL-S786 compared with those of other cephalosporins. Antimicrob Agents Chemother (1978) 1.62
The release of ribonuclease into the medium when E. coli cells are converted to spheroplasts. Biochem Biophys Res Commun (1964) 1.62
Comparison and evaluation of ticarcillin and carbenicillin using disk diffusion methods. Antimicrob Agents Chemother (1976) 1.62
In vitro activity and beta-lactamase stability of cefmenoxime. Antimicrob Agents Chemother (1982) 1.62
In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074). Antimicrob Agents Chemother (1986) 1.60
Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother (1979) 1.60
Antimicrobial activity and human pharmacology of amoxicillin. J Infect Dis (1974) 1.59
The role of Pseudomonas aeruginosa in infections. J Antimicrob Chemother (1983) 1.57